Skip to content
Clinical Trials – home
VerifiedinfoResponsive

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

Spain Calle Villarroel 170, 08036 Barcelona, Spain

  • 47 trials recruiting
  • HIV infection · Hepatic cirrhosis · Breast cancer
  • Adults and children

About Specializations

Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer in Barcelona, Spain specialises in clinical trials of conditions such as HIV infection, Hepatic cirrhosis, Breast cancer, Major depression, and other specialisations. This site conducts important research.

Main research areas of the site

Infectious Diseases and Viral Research

At Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer, the Infectious Diseases portfolio includes studies focused on HIV-1 infection and related immune responses, with an emphasis on improving treatment strategies and understanding how therapy can shape long-term disease control.

  • Evaluating new ways to support people living with HIV at the start of antiretroviral treatment
  • Studying the safety of adding a targeted therapy to reduce the viral reservoir
  • Advancing research in virus diseases and immune system diseases

This work aims to refine treatment approaches and improve outcomes for patients through safer and more effective clinical research.

Respiratory and Immune-Mediated Disease Studies

The site is conducting research in respiratory tract diseases and immune system diseases, especially for asthma, with trials designed to help maintain symptom control while exploring more convenient treatment strategies.

  • Testing whether adjusted treatment use can preserve stability in people with allergic asthma
  • Assessing effects on flare-ups, lung function, and quality of life
  • Supporting better long-term management of chronic airway disease

These studies focus on improving everyday disease control while keeping care practical and patient-centered.

Cardiovascular and Stroke Prevention Research

Clinical trials in cardiovascular diseases at this Barcelona research site are centered on reducing complications after acute ischemic stroke and managing atrial fibrillation, with broader interest in lowering future cardiovascular risk.

  • Studying early rhythm control to reduce serious outcomes after stroke
  • Exploring better strategies for patients with irregular heartbeat and vascular risk
  • Improving prevention of repeat events in high-risk heart and brain disease

The goal is to test treatment approaches that may help patients recover more safely and avoid additional cardiovascular events.

Metabolic and Digestive System Research

Research in digestive system diseases and related physiological processes includes studies in decompensated hepatic cirrhosis, where investigators are evaluating supportive care that may improve kidney recovery and overall clinical stability.

  • Assessing treatment options for acute kidney injury in advanced liver disease
  • Comparing approaches intended to improve organ function recovery
  • Addressing complications linked to severe liver disease

This line of research reflects a strong focus on managing complex illness at the intersection of digestive and renal health.

Oncology and Bladder Cancer Innovation

The oncology program covers neoplasms and includes trials in HER2 positive or HER2-low metastatic breast cancer, basal cell carcinoma, and non-muscle-invasive bladder cancer, with a clear focus on testing new treatment options and improving disease control.

  • Evaluating new therapies for advanced breast cancer
  • Studying targeted approaches for bladder cancer with specific genetic alterations
  • Investigating local treatment strategies for basal cell carcinoma

These studies aim to expand treatment choices for patients with difficult-to-treat cancers and support more personalized care.

Cardiometabolic Risk and Diagnostic Research

The site also explores analytical, diagnostic and therapeutic techniques and equipment through studies in heterozygous familial hypercholesterolaemia and related lipid disorders, seeking better ways to assess and manage long-term cardiovascular risk.

  • Testing treatments aimed at lowering LDL cholesterol in inherited lipid disease
  • Improving prevention of future cardiovascular complications
  • Supporting earlier and more effective risk reduction in high-cholesterol conditions

This research combines treatment evaluation with better disease monitoring to help patients with inherited metabolic risk.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Calle Villarroel 17008036 BarcelonaSpain
Recruiting now
47 trials
Conditions studied
134
Partner status
Verified

More sites in BarcelonaSpain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

175 clinical trials

Countries:SpainSpain
  • Participants:18–64 years
  • Sponsor:Zenas Biopharma (USA) LLC
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Sargramostim
  • Sponsor:Greenwich LifeSciences Inc.
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Vafidemstat
  • Sponsor:Oryzon Genomics S.A.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Glofitamab
  • Sponsor:F. Hoffmann-La Roche AG

HIV infection

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Region Midtjylland
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Human Serum Albumin
  • Sponsor:Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer

COVID-19

Recruiting
Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Remdesivir
  • Sponsor:Fundacion Fls De Lucha Contra El Sida Las Enfermedades Infecciosas Y La Promocion De La Salud Y La Ciencia
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide Acetate
  • Sponsor:University Medical Center Hamburg-Eppendorf
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).